What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
Drilon, A., Li, G., Dogan, S., Gounder, M., Shen, R., Arcila, M., Wang, L., Hyman, D.M., Hechtman, J., Wei, G., Cam, N.R., Christiansen, J., Luo, D., Maneval, E.C., Bauer, T., Patel, M., Liu, S.V., Ou, S.H.I., Farago, A., Shaw, A., Shoemaker, R.F., Lim, J., Hornby, Z., Multani, P., Ladanyi, M., Berger, M., Katabi, N., Ghossein, R., Ho, A.L.
Published in Annals of oncology (01.05.2016)
Published in Annals of oncology (01.05.2016)
Get full text
Journal Article
Entrectinib, a highly potent pan-Trk, ROS1, and ALK inhibitor, has broad-spectrum, histology-agnostic anti-tumor activity in molecularly defined cancers
Wei, G, Patel, R, Walsh, C, Barrera, M, Fagan, P, Murphy, D, Christiansen, J, Shoemaker, R, Hornby, Z, Li, G.G
Published in European journal of cancer (1990) (01.12.2016)
Published in European journal of cancer (1990) (01.12.2016)
Get full text
Journal Article
Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside
Ho, A, Wei, G, Maneval, E.C, Esquibel, V, Berger, M.F, Haque, S, Patel, R, Walsh, C, Hornby, Z, Multani, P, Li, G, Drilon, A
Published in European journal of cancer (1990) (01.12.2016)
Published in European journal of cancer (1990) (01.12.2016)
Get full text
Journal Article
78 - Entrectinib, a highly potent pan-Trk, ROS1, and ALK inhibitor, has broad-spectrum, histology-agnostic anti-tumor activity in molecularly defined cancers
Wei, G., Patel, R., Walsh, C., Barrera, M., Fagan, P., Murphy, D., Christiansen, J., Shoemaker, R., Hornby, Z., Li, G.G.
Published in European journal of cancer (1990) (01.12.2016)
Published in European journal of cancer (1990) (01.12.2016)
Get full text
Journal Article
P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions
Rangaraju, S., Farago, A., Heym, K. M., Ahn, M., Drilon, A., Potts, S., Hornby, Z., Multani, P., Li, G.
Published in Neuro-oncology (Charlottesville, Va.) (01.05.2017)
Published in Neuro-oncology (Charlottesville, Va.) (01.05.2017)
Get full text
Journal Article
8LBA - Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside
Ho, A., Wei, G., Maneval, E.C., Esquibel, V., Berger, M.F., Haque, S., Patel, R., Walsh, C., Hornby, Z., Multani, P., Li, G., Drilon, A.
Published in European journal of cancer (1990) (01.12.2016)
Published in European journal of cancer (1990) (01.12.2016)
Get full text
Journal Article
Improved efficacy response attributed to diagnostic selection – Interim results of the phase 1 experience from ALKA-372-001
Christiansen, J., Siena, S., Valtorta, E., Johnson, A., Murphy, D., Shoemaker, R., Lamoureux, J., Luo, D., Patel, R., Hornby, Z., Multani, P., Maneval, E. Chow, Duca, M., Debraud, F.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article